{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T08:50:26Z","timestamp":1772355026831,"version":"3.50.1"},"reference-count":178,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T00:00:00Z","timestamp":1467331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T00:00:00Z","timestamp":1467331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revista de Psiquiatr\u00eda  y Salud Mental"],"published-print":{"date-parts":[[2016,7]]},"DOI":"10.1016\/j.rpsm.2015.11.003","type":"journal-article","created":{"date-parts":[[2016,2,25]],"date-time":"2016-02-25T01:02:42Z","timestamp":1456362162000},"page":"158-173","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":46,"title":["Consenso espa\u00f1ol sobre los riesgos y detecci\u00f3n de la hiperprolactinemia iatrog\u00e9nica por antipsic\u00f3ticos"],"prefix":"10.1016","volume":"9","author":[{"given":"\u00c1ngel L.","family":"Montejo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Celso","family":"Arango","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miguel","family":"Bernardo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 L.","family":"Carrasco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benedicto","family":"Crespo-Facorro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan J.","family":"Cruz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier","family":"del Pino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miguel A.","family":"Garc\u00eda Escudero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clemente","family":"Garc\u00eda Rizo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Gonz\u00e1lez-Pinto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana I.","family":"Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuel","family":"Mart\u00edn Carrasco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fermin","family":"Mayoral Cleries","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaqueline","family":"Mayoral van Son","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. Teresa","family":"Mories","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabella","family":"Pachiarotti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salvador","family":"Ros","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eduard","family":"Vieta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"Suppl 2","key":"10.1016\/j.rpsm.2015.11.003_bib0900","first-page":"S10","article-title":"Physical health considerations in psychiatry: Views on recognition, monitoring and management","volume":"18","author":"Fagiolini","year":"2008","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1016\/j.rpsm.2015.11.003_bib0905","first-page":"251","article-title":"[Consensus on physical health of patients with schizophrenia from the Spanish Societies of Psychiatry and Biological Psychiatry] [art\u00edculo en espa\u00f1ol]","volume":"36","author":"S\u00e1iz Ruiz","year":"2008","journal-title":"Actas Esp Psiquiatr"},{"issue":"supl 2","key":"10.1016\/j.rpsm.2015.11.003_bib0910","first-page":"101","article-title":"Prolactin awareness: An essential consideration for physical health in schizophrenia","volume":"18","author":"Montejo","year":"2008","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1016\/j.rpsm.2015.11.003_bib0915","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1080\/00926230701866125","article-title":"Psychometric properties of the Psychotropic-Related Sexual Dysfunction Questionnaire (PRsexDQ-SALSEX) in patients with schizophrenia and other psychotic disorders","volume":"34","author":"Montejo","year":"2008","journal-title":"J Sex Marital Ther"},{"key":"10.1016\/j.rpsm.2015.11.003_bib0920","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1097\/jcp.0b013e31815ac4e5","article-title":"Clinical implications of antipsychotic-induced hyperprolactinemia in patients with schizophrenia spectrum or bipolar spectrum disorders: recent developments and current perspectives","volume":"27","author":"Byerly","year":"2007","journal-title":"J Clin Psychopharmacol"},{"issue":"1-3","key":"10.1016\/j.rpsm.2015.11.003_bib0925","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.schres.2008.05.009","article-title":"A comparison of schizophrenia outpatients treated with antipsychotics with and without metabolic syndrome: Findings from the CLAMORS study","volume":"104","author":"Arango","year":"2008","journal-title":"Schizophr Res."},{"key":"10.1016\/j.rpsm.2015.11.003_bib0930","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1177\/0269881107088435","article-title":"A review of the association between antipsychotic use and hyperprolactinaemia","volume":"22","author":"Bushe","year":"2008","journal-title":"J Psychopharmacol"},{"key":"10.1016\/j.rpsm.2015.11.003_bib0935","doi-asserted-by":"crossref","first-page":"57","DOI":"10.4088\/JCP.v65n0109","article-title":"Prolactin levels in schizophrenia and schizoaffective disorder patients treated with clozapine, olanzapine, risperidone, or haloperidol","volume":"65","author":"Volavka","year":"2004","journal-title":"J Clin Psychiatry."},{"key":"10.1016\/j.rpsm.2015.11.003_bib0940","doi-asserted-by":"crossref","first-page":"830","DOI":"10.3109\/00048674.2011.589044","article-title":"Antipsychotic-induced hyperprolactinaemia","volume":"45","author":"Inder","year":"2011","journal-title":"Aust N Z J Psychiatry"},{"key":"10.1016\/j.rpsm.2015.11.003_bib0945","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1177\/0269881112442016","article-title":"Prolactin, hyperprolactinaemia and antipsychotic treatment: A review and lessons for treatment of early psychosis","volume":"26","author":"Cookson","year":"2012","journal-title":"J Psychopharmacol"},{"key":"10.1016\/j.rpsm.2015.11.003_bib0950","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1089\/cap.2006.0039","article-title":"Antipsychotic-related abnormal involuntary movements and metabolic and endocrine side effects in children and adolescents","volume":"17","author":"Laita","year":"2007","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"10.1016\/j.rpsm.2015.11.003_bib0955","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s00115-006-2112-0","article-title":"[Differences between men and women in side effects of second-generation antipsychotics] [art\u00edculo en alem\u00e1n]","volume":"78","author":"Aichhorn","year":"2007","journal-title":"Der Nervenarzt"},{"key":"10.1016\/j.rpsm.2015.11.003_bib0960","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1097\/JCP.0b013e318272688b","article-title":"Long-term effect of haloperidol, olanzapine, and risperidone on plasma prolactin levels in patients with first-episode psychosis","volume":"32","author":"P\u00e9rez-Iglesias","year":"2012","journal-title":"J Clin Psychopharmacol."},{"key":"10.1016\/j.rpsm.2015.11.003_bib0965","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/1744-859X-12-42","article-title":"Reasons and clinical outcomes of antypsicotic treatment switch in outpatients with schizophrenia in real-life clinical settings: The ETOS observational study","volume":"12","author":"Roussidis","year":"2013","journal-title":"Ann Gen Psychiatry"},{"key":"10.1016\/j.rpsm.2015.11.003_bib0970","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/1471-244X-12-20","article-title":"A patient perspective of the impact of medication side effects on adherence: Results of a cross-sectional nationwide survey of patients with schizophrenia","volume":"12","author":"DiBonaventura","year":"2012","journal-title":"BMC Psychiatry"},{"issue":"1 Pt 2","key":"10.1016\/j.rpsm.2015.11.003_bib0975","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1111\/j.1743-6109.2009.01621.x","article-title":"Sexual function in chronic illness","volume":"7","author":"Basson","year":"2010","journal-title":"J Sex Med"},{"key":"10.1016\/j.rpsm.2015.11.003_bib0980","doi-asserted-by":"crossref","first-page":"3404","DOI":"10.1111\/j.1743-6109.2010.01709.x","article-title":"Frequency of sexual dysfunction in patients with a psychotic disorder receiving antipsychotics","volume":"7","author":"Montejo","year":"2010","journal-title":"J Sex Med."},{"key":"10.1016\/j.rpsm.2015.11.003_bib0985","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1210\/jc.2003-030306","article-title":"Diurnal profiles of testosterone and pituitary hormones suggest different mechanisms for menstrual disturbances in endurance athletes","volume":"89","author":"Rickenlund","year":"2004","journal-title":"J Clin Endocrinol Metab."},{"key":"10.1016\/j.rpsm.2015.11.003_bib0990","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1152\/physrev.2000.80.4.1523","article-title":"Prolactin: Structure, function and regulation of secretion","volume":"80","author":"Freeman","year":"2000","journal-title":"Physiol Rev."},{"key":"10.1016\/j.rpsm.2015.11.003_bib0995","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1056\/NEJM197801262980408","article-title":"Prolactin","volume":"298","author":"Frantz","year":"1978","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rpsm.2015.11.003_bib1000","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1210\/jc.2010-1692","article-title":"Diagnosis and treatment of hyperprolactinemia: An endocrine society clinical practice guideline","volume":"96","author":"Melmed","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.rpsm.2015.11.003_bib1005","first-page":"435","article-title":"Prolactin not only lactotrophin. A \u00abnew\u00bb view of the \u00abold\u00bb hormone","volume":"63","author":"Ignacak","year":"2012","journal-title":"J Physiol Pharmacol."},{"key":"10.1016\/j.rpsm.2015.11.003_bib1010","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1007\/BF01815271","article-title":"Control of prolactin secretion","volume":"68","author":"Benker","year":"1990","journal-title":"Klin Wochenschr."},{"key":"10.1016\/j.rpsm.2015.11.003_bib1015","series-title":"Summary of the regulation and effects of prolactin. In Chapter 5, The hypothalamus and pituitary gland","first-page":"66","author":"Holt","year":"2006"},{"issue":"Suppl","key":"10.1016\/j.rpsm.2015.11.003_bib1020","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/0196-9781(84)90259-6","article-title":"Recent studies on the role of brain peptides in control of anterior pituitary hormone secretion","volume":"5","author":"McCann","year":"1984","journal-title":"Peptides."},{"key":"10.1016\/j.rpsm.2015.11.003_bib1025","first-page":"249","article-title":"Neurotransmitter regulation of anterior pituitary hormones","volume":"37","author":"Tuomisto","year":"1985","journal-title":"Pharmacol Rev."},{"key":"10.1016\/j.rpsm.2015.11.003_bib1030","series-title":"Williams tratado de endocrinolog\u00eda","first-page":"159","article-title":"Adenohip\u00f3fisis","author":"Melmed","year":"2009"},{"key":"10.1016\/j.rpsm.2015.11.003_bib1035","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/0306-4530(81)90044-5","article-title":"Tuberoinfundibular dopamine neurons and regulation of ptolactin secretion","volume":"6","author":"Gudelsky","year":"1981","journal-title":"Psychoneuroendocrinology."},{"key":"10.1016\/j.rpsm.2015.11.003_bib1040","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1023\/B:BEBM.0000042707.46061.5d","article-title":"Immunoprotective effects of prolactin during stress induced immune dysfunction","volume":"137","author":"Formicheva","year":"2004","journal-title":"Bull Exp Biol Med."},{"key":"10.1016\/j.rpsm.2015.11.003_bib1045","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s11102-005-5082-5","article-title":"Prolactin and autoimmunity","volume":"8","author":"De Bellis","year":"2005","journal-title":"Pituitary"},{"key":"10.1016\/j.rpsm.2015.11.003_bib1050","first-page":"292","article-title":"The roles of prolactin, growth hormone, insulin-like growth factor-i, and thyroid hormones in lymphocyte development and function: Insights from genetic models of hormone and hormone receptor deficiency","volume":"21","author":"Dorshkind","year":"2000","journal-title":"Endocr Rev"},{"key":"10.1016\/j.rpsm.2015.11.003_bib1055","first-page":"575","article-title":"Diagnosis and management of hyper-prolactinemia","volume":"169","author":"Serri","year":"2003","journal-title":"CMAJ"},{"key":"10.1016\/j.rpsm.2015.11.003_bib1060","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1530\/eje.0.1480325","article-title":"Gender differences in the prevalence, clinical features and response to cabergoline in hyperprolactinemia","volume":"148","author":"Colao","year":"2003","journal-title":"Eur J Endocrinol."},{"issue":"Suppl 2","key":"10.1016\/j.rpsm.2015.11.003_bib1065","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0306-4530(02)00127-0","article-title":"Prevalence of hyperprolactinaemia in schizophrenic patients treated with conventional antipsychotic medications or risperidone","volume":"28","author":"Kinon","year":"2003","journal-title":"Psychoneuroendocrinol"},{"key":"10.1016\/j.rpsm.2015.11.003_bib1070","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.2165\/11204840-000000000-00000","article-title":"Paliperidone extended release: A review of its use in the management of schizophrenia","volume":"70","author":"Chwieduk","year":"2010","journal-title":"Drugs"},{"key":"10.1016\/j.rpsm.2015.11.003_bib1075","first-page":"5","article-title":"[Efficacy, tolerability and safety of paliperidone extended-release in the treatment of schizophrenia and schizoaffective disorder] [art\u00edculo en italiano]","volume":"47","author":"Bellantuono","year":"2012","journal-title":"Riv Psichiatr"},{"key":"10.1016\/j.rpsm.2015.11.003_bib1080","doi-asserted-by":"crossref","first-page":"869","DOI":"10.2147\/NDT.S1365","article-title":"Paliperidone ER: A review of the clinical trial data","volume":"3","author":"Janicak","year":"2007","journal-title":"Neuropsychiatr Dis Treat"},{"key":"10.1016\/j.rpsm.2015.11.003_bib1085","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.encep.2012.03.002","article-title":"[Antipsychotic-drug-induced hyperprolactinemia: Physiopathology, clinical features and guidance] [art\u00edculo en franc\u00e9s]","volume":"40","author":"Besnard","year":"2014","journal-title":"Encephale."},{"key":"10.1016\/j.rpsm.2015.11.003_bib1090","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.4088\/JCP.08m04307yel","article-title":"Positron emission tomography measurement of dopamine D receptor occupancy in the pituitary and cerebral cortex: Relation to antipsychotic-induced hyperprolactinemia","volume":"71","author":"Arakawa","year":"2010","journal-title":"J Clin Psychiatry."},{"key":"10.1016\/j.rpsm.2015.11.003_bib1095","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.pnpbp.2006.07.006","article-title":"Amisulpride-induced hyperprolactinemia is reversible following discontinuation","volume":"31","author":"Paparrigopoulos","year":"2007","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.rpsm.2015.11.003_bib1100","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1258\/acb.2010.010025","article-title":"A review of hyperprolactinaemia and severe mental illness: Are there implications for clinical biochemistry?","volume":"47","author":"Bushe","year":"2010","journal-title":"Ann Clin Biochem."},{"key":"10.1016\/j.rpsm.2015.11.003_bib1105","doi-asserted-by":"crossref","first-page":"205","DOI":"10.2147\/DHPS.S6226","article-title":"Safety and tolerability of antipsychotics: Focus on amisulpride","volume":"2","author":"Juruena","year":"2010","journal-title":"Drug Healthc Patient Saf"},{"key":"10.1016\/j.rpsm.2015.11.003_bib1110","first-page":"502697","article-title":"The effects of antipsychotics on prolactin levels and women's menstruation","author":"Bargiota","year":"2013","journal-title":"Schizophr Res Treatment"},{"key":"10.1016\/j.rpsm.2015.11.003_bib1115","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1192\/bjp.137.6.518","article-title":"Clinical state, plasma levels of haloperidol and prolactin: A correlation study in chronic schizophrenia","volume":"137","author":"Rao","year":"1980","journal-title":"Br J Psychiatry"},{"key":"10.1016\/j.rpsm.2015.11.003_bib1120","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/BF00434400","article-title":"Plasma fluphenazine and prolactin levels in schizophrenic patients during treatment with low and high doses of fluphenazine enanthate","volume":"71","author":"Wiles","year":"1980","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.rpsm.2015.11.003_bib1125","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1177\/0269881107088438","article-title":"The impact of hyperprolactinaemia on sexual function in patients with psychosis","volume":"22","author":"Smith","year":"2008","journal-title":"J Psychopharmacol"},{"key":"10.1016\/j.rpsm.2015.11.003_bib1130","first-page":"881","article-title":"Differences in the effect of second-generation antipsychotics on prolactinaemia: 6 weeks open-label trial in female in-patients","volume":"28","author":"Svestka","year":"2007","journal-title":"Neuro Endocrinol Lett"},{"key":"10.1016\/j.rpsm.2015.11.003_bib1135","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.rpsm.2010.10.003","article-title":"Asenapine: A new focus on the treatment of mania","volume":"4","author":"Cruz","year":"2011","journal-title":"Rev Psiquiatr Salud Ment."},{"key":"10.1016\/j.rpsm.2015.11.003_bib1140","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1097\/JCP.0b013e31818501a1","article-title":"Changes in sexual function for outpatients with schizophrenia or other psychotic disorders treated with ziprasidone in clinical practice settings: A 3-month, prospective, observational study","volume":"28","author":"Montejo","year":"2008","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.rpsm.2015.11.003_bib1145","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0920-9964(97)00036-4","article-title":"The acute and long-term effect of olanzapine compared with placebo and haloperidol on serum prolactin concentrations","volume":"26","author":"Crawford","year":"1997","journal-title":"Schizophr Res."},{"key":"10.1016\/j.rpsm.2015.11.003_bib1150","first-page":"421","article-title":"The effects of novel and newly approved antipsychotics on serum prolactin levels: A comprehensive review","volume":"28","author":"Peuskens","year":"2014","journal-title":"CNS Drugs"},{"key":"10.1016\/j.rpsm.2015.11.003_bib1155","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/S0140-6736(13)60733-3","article-title":"Comparative efficacy and tolerability of 15 antipsychoticdrugs in schizophrenia: A multiple-treatments meta-analysis","volume":"382","author":"Leucht","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.rpsm.2015.11.003_bib1160","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1016\/j.pnpbp.2010.02.019","article-title":"Hyperprolactinaemia in early psychosis-not only due to antipsychotics","volume":"34","author":"Aston","year":"2010","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry."},{"key":"10.1016\/j.rpsm.2015.11.003_bib1165","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.schres.2011.07.025","article-title":"Prolactin concentrations in newly diagnosed, antipsychotic-na\u00efve patients with nonaffective psychosis","volume":"134","author":"Garcia-Rizo","year":"2012","journal-title":"Schizophr Res."},{"key":"10.1016\/j.rpsm.2015.11.003_bib1170","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/S0140-6736(08)60486-9","article-title":"Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: An open randomised clinical trial","volume":"371","author":"Kahn","year":"2008","journal-title":"Lancet."},{"key":"10.1016\/j.rpsm.2015.11.003_bib1175","first-page":"17","article-title":"Baseline serum prolactin in drug-naive, first-episode schizophrenia and outcome at 5 years: Is it a predictive factor?","volume":"9","author":"Shrivastava","year":"2012","journal-title":"Innov Clin Neurosci."},{"key":"10.1016\/j.rpsm.2015.11.003_bib1180","doi-asserted-by":"crossref","first-page":"2571","DOI":"10.1017\/S0033291713000226","article-title":"Hyperprolactinemia in antipsychotic-naive patients with first-episode psychosis","volume":"43","author":"Riecher-R\u00f6ssler","year":"2013","journal-title":"Psychol Med"},{"key":"10.1016\/j.rpsm.2015.11.003_bib1185","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.psychres.2004.01.010","article-title":"Serum prolactin levels in unmedicated first-episode and recurrent schizophrenia patients: A possible marker for the disease's subtypes","volume":"127","author":"Segal","year":"2004","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.rpsm.2015.11.003_bib1190","doi-asserted-by":"crossref","unstructured":"Hernandez A.I., Montejo AL, Prieto N, S\u00e1nchez S, Gallego MT, Bote B, et al. EPA: 1694 Antipsychotics and prolactin. Study of prevalence and associated sexual dysfunction. Eur Psychiatr. 2014;29(Supp 1):1. Disponible en: http:\/\/dx.doi.org\/10.1016\/S0924-9338(14)78837-6","DOI":"10.1016\/S0924-9338(14)78837-6"},{"key":"10.1016\/j.rpsm.2015.11.003_bib1195","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1097\/JCP.0b013e3181faf0e3","article-title":"Prolactin levels and sexual adverse effects in patients with schizophrenia during antipsychotic treatment","volume":"30","author":"Rettenbacher","year":"2010","journal-title":"J Clin Psychopharmacol."},{"key":"10.1016\/j.rpsm.2015.11.003_bib1200","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1192\/bjp.bp.106.023671","article-title":"Risk of hip fracture in patients with a history ofschizophrenia","volume":"190","author":"Howard","year":"2007","journal-title":"Br J Psychiatry."},{"key":"10.1016\/j.rpsm.2015.11.003_bib1205","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S0079-6123(01)33015-7","article-title":"Neuroendocrine changes and fertility in breastfeeding women","volume":"133","author":"McNeilly","year":"2001","journal-title":"Prog Brain Res."},{"key":"10.1016\/j.rpsm.2015.11.003_bib1210","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1111\/j.1365-2265.2006.02562.x","article-title":"Guidelines of de pituitray society for the diagnosis and management of prolactinoma","volume":"65","author":"Casanueva","year":"2006","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.rpsm.2015.11.003_bib1215","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.ecl.2007.10.013","article-title":"Hyperprolactinemia and prolactinomas","volume":"37","author":"Mancini","year":"2008","journal-title":"Endocrinol Metab Clin North Am"},{"key":"10.1016\/j.rpsm.2015.11.003_bib1220","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1097\/MOU.0b013e32834bdf01","article-title":"Prolactin in men's health and disease","volume":"21","author":"Bolyakov","year":"2011","journal-title":"Curr Opin Urol."},{"key":"10.1016\/j.rpsm.2015.11.003_bib1225","doi-asserted-by":"crossref","first-page":"234","DOI":"10.20453\/rmh.v17i4.884","article-title":"Estados hiperprolactin\u00e9micos","volume":"17","author":"Solis","year":"2006","journal-title":"Red Med Hered."},{"key":"10.1016\/j.rpsm.2015.11.003_bib1230","first-page":"197","article-title":"Prolactinoma in children and adolescents","volume":"72","author":"Fideleff","year":"2009","journal-title":"Horm Res."},{"key":"10.1016\/j.rpsm.2015.11.003_bib1235","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.endonu.2012.11.005","article-title":"Gu\u00eda cl\u00ednica de diagn\u00f3stico y tratamiento del prolactinoma y la hiperprolactinemia","volume":"60","author":"Halperin","year":"2013","journal-title":"Endocrinol Nutr."},{"key":"10.1016\/j.rpsm.2015.11.003_bib1240","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.bpobgyn.2007.08.002","article-title":"Hyperprolactinemia","volume":"22","author":"Prabhakar","year":"2008","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"key":"10.1016\/j.rpsm.2015.11.003_bib1245","doi-asserted-by":"crossref","first-page":"168","DOI":"10.4103\/0974-1208.121400","article-title":"Hyperprolactinemia","volume":"6","author":"Majumdar","year":"2013","journal-title":"J Hum Reprod Sci"},{"key":"10.1016\/j.rpsm.2015.11.003_bib1250","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1210\/jcem-64-5-1021","article-title":"Forearm and vertebral bone mineral in treated and untreated hyperprolactinemic amenorrhea","volume":"64","author":"Schlechte","year":"1987","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.rpsm.2015.11.003_bib1255","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1080\/713847170","article-title":"Frequency of sexual dysfunction and other reproductive side-effects in patients with schizophrenia treated with risperidone, olanzapine, quetiapine, or haloperidol: The results of the EIRE study","volume":"29","author":"Bobes","year":"2003","journal-title":"J Sex Marital Ther."},{"key":"10.1016\/j.rpsm.2015.11.003_bib1260","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.eurpsy.2007.01.001","article-title":"Sexual dysfunction in patients with schizophrenia on antipsychotic medication","volume":"22","author":"\u00dc\u00e7ok","year":"2007","journal-title":"Eur Psychiatry"},{"key":"10.1016\/j.rpsm.2015.11.003_bib1265","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1097\/01.jcp.0000186872.04984.56","article-title":"6-month prospective observational study on the effects of quetiapine on sexual functioning","volume":"5","author":"Montejo Al","year":"2005","journal-title":"J Clin Psychopharmacol."},{"key":"10.1016\/j.rpsm.2015.11.003_bib1270","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1097\/01.jcp.0000106220.36344.04","article-title":"A randomized open- label study of the impact of quetiapine versus risperidone on sexual functioning","volume":"24","author":"Knegtering","year":"2004","journal-title":"J Clin Psychopharmacol."},{"key":"10.1016\/j.rpsm.2015.11.003_bib1275","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1080\/00926230600666378","article-title":"A randomized open-label comparison of the impact of olanzapine versus risperidone on sexual functioning","volume":"32","author":"Knegtering","year":"2006","journal-title":"J Sex Marital Ther."},{"key":"10.1016\/j.rpsm.2015.11.003_bib1280","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1097\/YIC.0b013e32835ba832","article-title":"Changes in prolactin levels and sexual function in young psychotic patients after switching from long-acting injectable risperidone to paliperidone palmitate","volume":"28","author":"Montalvo","year":"2013","journal-title":"Int Clin Psychopharmacol."},{"key":"10.1016\/j.rpsm.2015.11.003_bib1285","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1097\/YIC.0b013e328341e434","article-title":"A meta-analysis of sexual dysfunction in psychiatric patients taking antipsychotics","volume":"26","author":"Serretti","year":"2011","journal-title":"Int Clin Psychopharmacol."},{"key":"10.1016\/j.rpsm.2015.11.003_bib1290","first-page":"31","article-title":"Antipsychotics and sexual dysfunction: Epidemiology, mechanisms and management","volume":"10","author":"Chiesa","year":"2013","journal-title":"Clin Neuropsychia"},{"key":"10.1016\/j.rpsm.2015.11.003_bib1295","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1111\/j.1743-6109.2007.00569.x","article-title":"Effect of hyperprolactinemia in male patients consulting for sexual dysfunction","volume":"4","author":"Corona","year":"2007","journal-title":"J Sex Med"},{"key":"10.1016\/j.rpsm.2015.11.003_bib1300","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1111\/j.1743-6109.2012.02735.x","article-title":"Hormonal causes of male sexual disfunctions and their management (hyperprolactinemia, thyroid disorders, GH disorders, and DHEA)","volume":"10","author":"Maggi","year":"2013","journal-title":"J Sex Med"},{"key":"10.1016\/j.rpsm.2015.11.003_bib1305","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1097\/01.ju.0000176456.50491.51","article-title":"Sexual dysfunction in women with hyperprolactinemia: A pilot study report","volume":"174","author":"Kadioglu","year":"2005","journal-title":"J Urol"},{"key":"10.1016\/j.rpsm.2015.11.003_bib1310","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1097\/00131746-200101000-00005","article-title":"Which side effects really matter? Screening for common and distressing side effects of antipsychotic medications","volume":"7","author":"Weiden","year":"2001","journal-title":"J Psychiatr Pract."},{"key":"10.1016\/j.rpsm.2015.11.003_bib1315","doi-asserted-by":"crossref","first-page":"331","DOI":"10.4088\/JCP.v66n0309","article-title":"Male sexual dysfunction and quality of life in schizophrenia","volume":"66","author":"Olfson","year":"2005","journal-title":"J Clin Psychiatry."},{"key":"10.1016\/j.rpsm.2015.11.003_bib1320","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/j.1600-0447.2008.01310.x","article-title":"Side-effects of antipsychotic medication and health-related quality of life in schizophrenia","author":"Bebbington","year":"2009","journal-title":"Acta Psychiatr Scand Suppl."},{"key":"10.1016\/j.rpsm.2015.11.003_bib1325","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1080\/00926230390195524","article-title":"A survey of sexual side effects among severely mentally ill patients taking psychotropic medications: Impact on compliance","volume":"29","author":"Rosenberg","year":"2003","journal-title":"J Sex Marital Ther."},{"key":"10.1016\/j.rpsm.2015.11.003_bib1330","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1159\/000126626","article-title":"The impact of mental illness on sexual dysfunction","volume":"29","author":"Zemishlany","year":"2008","journal-title":"Adv Psychosom Med."},{"key":"10.1016\/j.rpsm.2015.11.003_bib1335","doi-asserted-by":"crossref","unstructured":"Montejo AL, Montero Fernandez C, Pol Rodriguez J, Esquer Terrazas I, Romero del R\u00edo O, Fernandez Martin L.C., Dutil Mu\u00f1oz V, et al. EPA-1652 Sexuality and emotional life in people with severe long-term mental. Disorders Eur Psychiatr. 2014;(29 suppl):1. Disponible en:http:\/\/dx.doi.org\/10.1016\/S0924-9338(14)78798-X","DOI":"10.1016\/S0924-9338(14)78798-X"},{"issue":"Suppl 1","key":"10.1016\/j.rpsm.2015.11.003_bib1340","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S0306-4530(02)00113-0","article-title":"Sexual dysfunction and antipsychotic treatment","volume":"28","author":"Cutler","year":"2003","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.rpsm.2015.11.003_bib1345","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.2165\/00003495-200464200-00003","article-title":"Antipsychotic-induced hyperprolactinaemia: Mechanisms, clinical features and management","volume":"64","author":"Haddad","year":"2004","journal-title":"Drugs"},{"key":"10.1016\/j.rpsm.2015.11.003_bib1350","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1002\/hup.924","article-title":"Sexual dysfunction in schizophrenia: Focus on recent evidence","volume":"23","author":"Baggaley","year":"2008","journal-title":"Hum Psychopharmacol."},{"key":"10.1016\/j.rpsm.2015.11.003_bib1355","series-title":"Standard practice in sexual medicine.","first-page":"225","article-title":"Hormones, metabolism, aging, and men's health","author":"Buvat","year":"2006"},{"key":"10.1016\/j.rpsm.2015.11.003_bib1360","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/0031-9384(81)90023-8","article-title":"Short-term endogenus hyperprolactinemia and sexual behavior of me rats","volume":"26","author":"Drago","year":"1981","journal-title":"Physiol Behav"},{"key":"10.1016\/j.rpsm.2015.11.003_bib1365","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1210\/rp.57.1.435","article-title":"Prolactin modulation of immune and inflammatory responses","volume":"57","author":"Yu-Lee","year":"2002","journal-title":"Recent Prog Horm Res."},{"key":"10.1016\/j.rpsm.2015.11.003_bib1370","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1038\/labinvest.3700256","article-title":"Prolactin stimulates integrin-mediated adhesion of circulating mononuclear cells to endothelial cells","volume":"85","author":"Montes de Oca","year":"2005","journal-title":"Lab Invest."},{"key":"10.1016\/j.rpsm.2015.11.003_bib1375","doi-asserted-by":"crossref","first-page":"4080","DOI":"10.1210\/en.2006-1577","article-title":"Prolactin induces regional vasoconstriction through the beta2-adrenergic and nitric oxide mechanisms","volume":"148","author":"Molinari","year":"2007","journal-title":"Endocrinology."},{"key":"10.1016\/j.rpsm.2015.11.003_bib1380","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.pnpbp.2011.11.016","article-title":"Sexual dysfunction and hyperprolactinemia in Japanese schizophrenic patients taking antipsychotics","volume":"37","author":"Kikuchi","year":"2012","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry."},{"key":"10.1016\/j.rpsm.2015.11.003_bib1385","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1186\/1471-244X-13-214","article-title":"Treating symptomatic hyperprolactinemia in women with schizophrenia: Presentation of the ongoing DAAMSEL Clinical Trial (Dopamine partial Agonist, Aripiprazole, for the Management of Symptomatic ELevated Prolactin)","volume":"13","author":"Deanna","year":"2013","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.rpsm.2015.11.003_bib1390","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1159\/000119265","article-title":"Galactorrhea and hyperprolactinemia in schizophrenic patients on neuroleptics: Frequency and etiology","volume":"33","author":"Windgassen","year":"1996","journal-title":"Neuropsychobiology."},{"key":"10.1016\/j.rpsm.2015.11.003_bib1395","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1056\/NEJM197703172961103","article-title":"Galactorrhea: A study of 235 cases, incluiding 48 with pituitary tumors","volume":"296","author":"Kleinberg","year":"1977","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rpsm.2015.11.003_bib1400","doi-asserted-by":"crossref","first-page":"165","DOI":"10.7326\/0003-4819-87-2-165","article-title":"Galactorrhea-amenorrhea syndrome: Diagnosis and therapy","volume":"87","author":"Boyd","year":"1977","journal-title":"Ann Intern Med."},{"key":"10.1016\/j.rpsm.2015.11.003_bib1405","first-page":"1085","article-title":"Clinical presentation of hyperprolactinemia","volume":"44","author":"Luciano","year":"1999","journal-title":"J Reprod Med."},{"key":"10.1016\/j.rpsm.2015.11.003_bib1410","first-page":"70","article-title":"Euprolactinemic gynecomastia and galactorrhea with risperidone-fluvoxamine combination","volume":"44","author":"Pratheesh","year":"2011","journal-title":"Psychopharmacol Bull."},{"key":"10.1016\/j.rpsm.2015.11.003_bib1415","doi-asserted-by":"crossref","first-page":"5555","DOI":"10.1210\/endo.138.12.5605","article-title":"Expression of prolactin and its receptor in human breast carcinoma","volume":"138","author":"Reynolds","year":"1997","journal-title":"Endocrinology"},{"key":"10.1016\/j.rpsm.2015.11.003_bib1420","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1097\/PSY.0b013e3181f7abd3","article-title":"Skeletal status in psychotic disorders: A population-based study","volume":"72","author":"Partti","year":"2010","journal-title":"Psychosom Med."},{"key":"10.1016\/j.rpsm.2015.11.003_bib1425","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/hup.1265","article-title":"Is antipsychotic treatment linked to low bone mineral density and osteoporosis? A review of the evidence and the clinical implications","volume":"27","author":"Crews","year":"2012","journal-title":"Hum Psychopharmacol"},{"key":"10.1016\/j.rpsm.2015.11.003_bib1430","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2474-10-1","article-title":"Bone mass in schizophrenia and normal populations across different decades of life","volume":"10","author":"Renn","year":"2009","journal-title":"BMC Musculoskelet Disord."},{"key":"10.1016\/j.rpsm.2015.11.003_bib1435","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.4088\/JCP.v69n0907","article-title":"Sex and age-specific incidence of fractures in mental illness: A historical, population-based cohort study","volume":"69","author":"Abel","year":"2008","journal-title":"J Clin Psychiatry."},{"key":"10.1016\/j.rpsm.2015.11.003_bib1440","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1111\/j.1525-1497.2006.00563.x","article-title":"Medical comorbidity in women and men with schizophrenia: A population-based controlled study","volume":"21","author":"Carney","year":"2006","journal-title":"J Gen Intern Med."},{"key":"10.1016\/j.rpsm.2015.11.003_bib1445","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1177\/0004867412449876","article-title":"Tobacco smoking among people living with a psychotic illness: The second Australian Survey of Psychosis","volume":"46","author":"Cooper","year":"2012","journal-title":"Aust N Z J Psychiatry."},{"key":"10.1016\/j.rpsm.2015.11.003_bib1450","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/1471-244X-10-38","article-title":"Dietary intake of fish, omega-3, omega-6 polyunsaturated fatty acids and vitamin D and the prevalence of psychotic-like symptoms in a cohort of 33,000 women from the general population","volume":"26","author":"Hedelin","year":"2010","journal-title":"BMC Psychiatry."},{"key":"10.1016\/j.rpsm.2015.11.003_bib1455","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1097\/01.jcp.0000150223.31007.e0","article-title":"Antipsychotic drugs: A new risk factor for osteoporosis in young women with schizophrenia?","volume":"25","author":"O\u2019Keane","year":"2005","journal-title":"J Clin Psychopharmacol."},{"key":"10.1016\/j.rpsm.2015.11.003_bib1460","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.schres.2013.04.015","article-title":"The impact of prolactin-raising antipsychotics on bone mineral density in patients with schizophrenia: Findings from a longitudinal observational cohort","volume":"147","author":"Takahashi","year":"2013","journal-title":"Schizophr Res."},{"key":"10.1016\/j.rpsm.2015.11.003_bib1465","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.schres.2012.10.031","article-title":"Bone mineral density as a marker of cumulative endogenous estrogen exposure: Relationship to background genetic risk of psychotic disorder","volume":"143","author":"Van der Leeuw","year":"2013","journal-title":"Schizophr Res."},{"key":"10.1016\/j.rpsm.2015.11.003_bib1470","doi-asserted-by":"crossref","first-page":"115","DOI":"10.3371\/CSRP.KISE.020113","article-title":"Bone loss associated with hyperprolactinemia in patients with schizophrenia","volume":"7","author":"Kinon","year":"2013","journal-title":"Clin Schizophr Relat Psychoses."},{"key":"10.1016\/j.rpsm.2015.11.003_bib1475","doi-asserted-by":"crossref","first-page":"385","DOI":"10.4088\/JCP.v69n0307","article-title":"Antipsychotic-induced hyperprolactinemia inhibits the hypothalamo-pituitary-gonadal axis and reduces bone mineral density in male patients with schizophrenia","volume":"69","author":"Kishimoto","year":"2008","journal-title":"J Clin Psychiatry."},{"key":"10.1016\/j.rpsm.2015.11.003_bib1480","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1002\/jcb.22161","article-title":"Evidence for direct effects of prolactin on human osteoblasts: Inhibition of cell growth and mineralization","volume":"107","author":"Seriwatanachai","year":"2009","journal-title":"J Cell Biochem."},{"key":"10.1016\/j.rpsm.2015.11.003_bib1485","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1007\/s12020-011-9462-5","article-title":"Vertebral fractures in males with prolactinoma","volume":"39","author":"Mazziotti","year":"2011","journal-title":"Endocrine."},{"key":"10.1016\/j.rpsm.2015.11.003_bib1490","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1001\/archpsyc.59.12.1147","article-title":"Dopamine antagonists and the development of breast cancer","volume":"59","author":"Wang","year":"2002","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.rpsm.2015.11.003_bib1495","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1007\/s12672-013-0165-7","article-title":"Prolactin receptor expression and breast cancer: Relationships with tumor characteristics among pre- and post-menopausal women in a population-based case-control study from Poland","volume":"5","author":"Faupel-Badger","year":"2014","journal-title":"Horm Cancer."},{"key":"10.1016\/j.rpsm.2015.11.003_bib1500","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1210\/er.2001-0036","article-title":"The role of prolactin in mammary carcinoma","volume":"24","author":"Clevenger","year":"2003","journal-title":"Endocr Rev"},{"key":"10.1016\/j.rpsm.2015.11.003_bib1505","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1210\/er.2004-0016","article-title":"Development and potential clinical uses of human prolactin receptor antagonists","volume":"26","author":"Goffin","year":"2005","journal-title":"Endocr Rev"},{"key":"10.1016\/j.rpsm.2015.11.003_bib1510","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1191\/0960327106ht643oa","article-title":"Hyperprolactinaemia as an adverse effect in regulatory and clinical toxicology: Role in breast and prostate cancer","volume":"25","author":"Harvey","year":"2006","journal-title":"Hum Exp Toxicol."},{"key":"10.1016\/j.rpsm.2015.11.003_bib1515","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1093\/jnci\/91.7.629","article-title":"Plasma prolactin levels and subsequent risk of breast cancer in postmenopausal women","volume":"91","author":"Hankinson","year":"1999","journal-title":"J Natl Cancer Inst."},{"key":"10.1016\/j.rpsm.2015.11.003_bib1520","first-page":"599","article-title":"Postmenopausal breast cancer risk in relation to sex steroid hormones, prolactin and SHBG (Sweden)","volume":"14","author":"Manjer","year":"2003","journal-title":"Cancer Causes Control."},{"key":"10.1016\/j.rpsm.2015.11.003_bib1525","doi-asserted-by":"crossref","first-page":"2476","DOI":"10.1158\/0008-5472.CAN-05-3369","article-title":"Association between plasma prolactin concentrations and risk of breast cancer among predominately premenopausal women","volume":"66","author":"Tworoger","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.rpsm.2015.11.003_bib1530","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1200\/JCO.2006.07.6356","article-title":"A prospective study of plasma prolactin concentrations and risk of premenopausal and postmenopausal breast cancer","volume":"25","author":"Tworoger","year":"2007","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.rpsm.2015.11.003_bib1535","doi-asserted-by":"crossref","first-page":"4810","DOI":"10.1158\/0008-5472.CAN-13-0665","article-title":"20-year prospective study of plasma prolactin as a risk marker of breast cancer development","volume":"73","author":"Tworoger","year":"2013","journal-title":"Cancer Res."},{"key":"10.1016\/j.rpsm.2015.11.003_bib1540","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s10911-008-9063-y","article-title":"Prolactin and breast cancer etiology: An epidemiologic perspective","volume":"13","author":"Tworoger","year":"2008","journal-title":"J Mammary Gland Biol Neoplasia"},{"key":"10.1016\/j.rpsm.2015.11.003_bib1545","doi-asserted-by":"crossref","first-page":"7677","DOI":"10.1073\/pnas.0502178102","article-title":"Serum protein markers for early detection of ovarian cancer","volume":"102","author":"Mor","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.rpsm.2015.11.003_bib1550","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.ygyno.2007.05.041","article-title":"Development of multimarker panel for early detection of endometrial cancer. High diagnostic power of prolactin","volume":"107","author":"Yurkovetsky","year":"2007","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.rpsm.2015.11.003_bib1555","doi-asserted-by":"crossref","first-page":"5226","DOI":"10.1158\/0008-5472.CAN-08-4652","article-title":"Biological significance of prolactin in gynecological cancers","volume":"69","author":"Levina","year":"2009","journal-title":"Cancer Res."},{"key":"10.1016\/j.rpsm.2015.11.003_bib1560","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1002\/ijc.1191","article-title":"Plasma prolactin and prostate cancer risk: A prospective study","volume":"92","author":"Stattin","year":"2001","journal-title":"Int J Cancer"},{"key":"10.1016\/j.rpsm.2015.11.003_bib1565","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1530\/EJE-11-0076","article-title":"Cancer risk in hyperprolactinemia patients: A population-based cohort study","volume":"165","author":"Berinder","year":"2011","journal-title":"Eur J Endocrinol."},{"key":"10.1016\/j.rpsm.2015.11.003_bib1570","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1161\/HYPERTENSIONAHA.109.132100","article-title":"Prolactin and preclinical atherosclerosis in menopausal women with cardiovascular risk factors","volume":"54","author":"Georgiopoulos","year":"2009","journal-title":"Hypertension"},{"key":"10.1016\/j.rpsm.2015.11.003_bib1575","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1007\/s11102-008-0097-3","article-title":"The effects of hyperprolactinemia on bone and fat","volume":"12","author":"Shibli-Rahhal","year":"2009","journal-title":"Pituitary."},{"key":"10.1016\/j.rpsm.2015.11.003_bib1580","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1111\/j.1365-2265.2009.03752.x","article-title":"Blood coagulation, fibrinolysis and lipid profile in patients with prolactinoma","volume":"73","author":"Erem","year":"2010","journal-title":"Clin Endocrinol (Oxf)."},{"key":"10.1016\/j.rpsm.2015.11.003_bib1585","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1111\/j.1365-2265.2011.04075.x","article-title":"The association of serum prolactin concentration with inflammatory biomarkers\u2013cross-sectional findings from the population-based study of health in Pomerania","volume":"75","author":"Friedrich","year":"2011","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.rpsm.2015.11.003_bib1590","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1530\/eje.0.1490187","article-title":"Endothelial function, insulin sensitivity and inflammatory markers in hyperprolactinemic pre-menopausal women","volume":"149","author":"Yavuz","year":"2003","journal-title":"Eur J Endocrinol."},{"key":"10.1016\/j.rpsm.2015.11.003_bib1595","first-page":"433","article-title":"Significance of heme oxygenase in prolactin-mediated cell proliferation and angiogenesis in human endothelial cells","volume":"10","author":"Malaguarnera","year":"2002","journal-title":"Int J Mol Med"},{"key":"10.1016\/j.rpsm.2015.11.003_bib1600","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.mce.2005.01.005","article-title":"Prolactin induced expression of vascular endothelial growth factor via Egr-1","volume":"232","author":"Goldhar","year":"2005","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.rpsm.2015.11.003_bib1605","doi-asserted-by":"crossref","first-page":"5912","DOI":"10.1210\/jcem.86.12.8085","article-title":"PRL as a novel potent cofactor for platelet aggregation","volume":"86","author":"Wallaschofski","year":"2001","journal-title":"J Clin Endocrinol Metab."},{"key":"10.1016\/j.rpsm.2015.11.003_bib1610","doi-asserted-by":"crossref","first-page":"447","DOI":"10.4158\/EP13173.OR","article-title":"Preclinical atherosclerosis in patients with prolactinoma","volume":"20","author":"Arslan","year":"2014","journal-title":"Endocr Pract"},{"key":"10.1016\/j.rpsm.2015.11.003_bib1615","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1161\/CIRCGENETICS.109.853572","article-title":"Prolactin levels and the risk of future coronary artery disease in apparently healthy men and women","volume":"2","author":"Reuwer","year":"2009","journal-title":"Circ Cardiovasc Genet"},{"key":"10.1016\/j.rpsm.2015.11.003_bib1620","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1677\/JOE-10-0076","article-title":"The prolactin receptor is expressed in macrophages within human carotid atherosclerotic plaques: A role for prolactin in atherogenesis?","volume":"208","author":"Reuwer","year":"2011","journal-title":"J Endocrinol."},{"key":"10.1016\/j.rpsm.2015.11.003_bib1625","first-page":"110","article-title":"Focus on prolactin as a metabolic hormone. Trends in endocrinology andmetabolism","volume":"17","author":"Ben-Jonathan","year":"2006","journal-title":"TEM"},{"key":"10.1016\/j.rpsm.2015.11.003_bib1630","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1111\/j.1463-1326.2006.00671.x","article-title":"Adipocyte prolactin: Regulation of release and putative functions","volume":"9","author":"Brandebourg","year":"2007","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.rpsm.2015.11.003_bib1635","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1210\/jc.2002-021137","article-title":"Identification of functional prolactin (PRL) receptor gene expression: PRL inhibits lipoprotein lipase activity in human white adipose tissue","volume":"88","author":"Ling","year":"2003","journal-title":"J Clin Endocrinol Metab."},{"key":"10.1016\/j.rpsm.2015.11.003_bib1640","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1038\/oby.2008.297","article-title":"Prolactin and insulin ultradian secretion and adipose tissue lipoprotein lipase expression in severely obese women after bariatric surgery","volume":"16","author":"Mingrone","year":"2008","journal-title":"Obesity (Silver Spring)"},{"key":"10.1016\/j.rpsm.2015.11.003_bib1645","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1210\/endo.143.4.8722","article-title":"Targeted deletion of the PRL receptor: Effects on islet development, insulin production, and glucose tolerance","volume":"143","author":"Freemark","year":"2002","journal-title":"Endocrinology"},{"key":"10.1016\/j.rpsm.2015.11.003_bib1650","doi-asserted-by":"crossref","first-page":"4162","DOI":"10.1210\/en.2004-0201","article-title":"Distinctive roles for prolactinand growth hormone in the activation of signal transducer and activatorof transcription 5 in pancreatic islets of langerhans","volume":"145","author":"Brelje","year":"2004","journal-title":"Endocrinology"},{"key":"10.1016\/j.rpsm.2015.11.003_bib1655","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1111\/j.1365-2265.2006.02469.x","article-title":"The influences of hyperprolactinemia and obesity on cardiovascular risk markers: Effects of cabergoline therapy","volume":"64","author":"Serri","year":"2006","journal-title":"Clin Endocrinol (Oxf)."},{"key":"10.1016\/j.rpsm.2015.11.003_bib1660","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1007\/s11695-009-9856-0","article-title":"Basal serum prolactin levels in obesity\u2013 unrelated to parameters of the metabolic syndrome and unchanged after massive weight loss","volume":"19","author":"Ernst","year":"2009","journal-title":"Obes Surg"},{"key":"10.1016\/j.rpsm.2015.11.003_bib1665","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1472-6823-13-12","article-title":"Serum prolactin concentrations as risk factor of metabolic syndrome or type 2 diabetes?","volume":"13","author":"Balbach","year":"2013","journal-title":"Endocr Dis"},{"key":"10.1016\/j.rpsm.2015.11.003_bib1670","first-page":"392","article-title":"Prolactinoma and body weight: A retrospective study","volume":"125","author":"Creemers","year":"1991","journal-title":"Acta Endocrinol"},{"key":"10.1016\/j.rpsm.2015.11.003_bib1675","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1046\/j.1365-2265.1999.00700.x","article-title":"Hyperprolactinaemia as a reversible cause of weight gain in male patients?","volume":"50","author":"Delgrange","year":"1999","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.rpsm.2015.11.003_bib1680","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1530\/eje.0.1470077","article-title":"Dopaminergic tone and obesity: An insight from prolactinomas treated with bromocriptine","volume":"147","author":"Doknic","year":"2002","journal-title":"Eur J Endocrinol."},{"key":"10.1016\/j.rpsm.2015.11.003_bib1685","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1016\/j.bbrc.2005.04.026","article-title":"Prolactin and growth hormone regulate adiponectin secretion and receptor expression in adipose tissue","volume":"331","author":"Nilsson","year":"2005","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.rpsm.2015.11.003_bib1690","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/S1568-9972(02)00081-2","article-title":"Prolactin and autoimmunity","volume":"1","author":"Vera-Lastra","year":"2002","journal-title":"Autoimmun Rev."},{"key":"10.1016\/j.rpsm.2015.11.003_bib1695","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1002\/cbf.1227","article-title":"The relationship between serum prolactin levels and disease activity in patients with Beh\u00e7et's disease","volume":"24","author":"Atasoy","year":"2006","journal-title":"Cell Biochem Funct"},{"key":"10.1016\/j.rpsm.2015.11.003_bib1700","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1093\/rheumatology\/kei115","article-title":"Serum free prolactin concentrations in patients with systemic lupus erythematosus are associated with lupus activity","volume":"45","author":"Leanos-Miranda","year":"2006","journal-title":"Rheumatology"},{"key":"10.1016\/j.rpsm.2015.11.003_bib1705","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.euroneuro.2008.04.014","article-title":"Increased incidence of autoimmune thyroiditis in patients with antipsychotic- induced hyperprolactinemia","volume":"18","author":"Poyraz","year":"2008","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1016\/j.rpsm.2015.11.003_bib1710","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.autrev.2006.10.005","article-title":"Hyperprolactinemia and autoinmune diseases","volume":"6","author":"Orbach","year":"2007","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.rpsm.2015.11.003_bib1715","doi-asserted-by":"crossref","first-page":"A465","DOI":"10.1016\/j.autrev.2011.11.009","article-title":"Prolantin and autoimmunity","volume":"11","author":"Shelly","year":"2012","journal-title":"Autoimmun Rev."},{"key":"10.1016\/j.rpsm.2015.11.003_bib1720","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1037\/a0025540","article-title":"Hormones and cognitive functioning during late pregnancy and pospartum: A longitudinal study","volume":"126","author":"Henry","year":"2012","journal-title":"Behav Neurosci"},{"key":"10.1016\/j.rpsm.2015.11.003_bib1725","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/0306-4530(92)90007-T","article-title":"Effects of estrogen on memory function in surgically menopausal women","volume":"17","author":"Phillips","year":"1992","journal-title":"Psychoneuroendocrinology."},{"key":"10.1016\/j.rpsm.2015.11.003_bib1730","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/j.psyneuen.2006.05.004","article-title":"Effects of treatment with luprolide acetate depot on working memory and executive functions in young premenopausal women","volume":"31","author":"Grigorova","year":"2006","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.rpsm.2015.11.003_bib1735","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1016\/j.psyneuen.2007.09.009","article-title":"Gonadotropin hormone releasing hormone agonists alter prefrontal function during verbal encoding in young women","volume":"32","author":"Craig","year":"2007","journal-title":"Psychoneuroendocrinology."},{"key":"10.1016\/j.rpsm.2015.11.003_bib1740","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.yhbeh.2008.01.012","article-title":"A study of visuospatial working memory pre- and post-gonadotropin hormone releasing hormone agonists (GnRHa) in young women","volume":"54","author":"Craig","year":"2008","journal-title":"Horm Behav."},{"key":"10.1016\/j.rpsm.2015.11.003_bib1745","doi-asserted-by":"crossref","first-page":"5001","DOI":"10.1210\/jc.2002-020419","article-title":"Longitudinal assessment of serum free testosterone concentration predicts memory performance and cognitive status in elderly men","volume":"87","author":"Moffat","year":"2002","journal-title":"J Clin Endocrinol Metab."},{"key":"10.1016\/j.rpsm.2015.11.003_bib1750","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/S0022-5347(05)00049-2","article-title":"Testosterone loss and estradiol administration modify memory in men","volume":"175","author":"Beer","year":"2006","journal-title":"J Urol."},{"key":"10.1016\/j.rpsm.2015.11.003_bib1755","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1177\/1756287210369805","article-title":"Hypogonadism, ADAM, and hormone replacement","volume":"2","author":"Pinsky","year":"2010","journal-title":"Ther Adv Urol"},{"key":"10.1016\/j.rpsm.2015.11.003_bib1760","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1212\/WNL.62.2.188","article-title":"Free testosterone and risk for Alzheimer disease in older men","volume":"62","author":"Moffat","year":"2004","journal-title":"Neurology"},{"issue":"1\u20134","key":"10.1016\/j.rpsm.2015.11.003_bib1765","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1159\/000287773","article-title":"Psychosomatic aspects of hyperprolactinemia","volume":"40","author":"Fava","year":"1983","journal-title":"Psychother Psychosom"},{"key":"10.1016\/j.rpsm.2015.11.003_bib1770","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1046\/j.1365-2265.1997.2701073.x","article-title":"Psychological distress in patients with hyperprolactinaemia","volume":"47","author":"Reavley","year":"1997","journal-title":"Clin Endocrinol."},{"key":"10.1016\/j.rpsm.2015.11.003_bib1775","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1590\/S0004-282X2000000400012","article-title":"Hiperprolactinemia e dist\u00farbios psiqui\u00e1tricos","volume":"58","author":"Oliveira","year":"2000","journal-title":"Arq Neuropsiquiatr"},{"key":"10.1016\/j.rpsm.2015.11.003_bib1780","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1159\/000012273","article-title":"Emotional aspects of hyperprolactinemia","volume":"67","author":"Sobrinho","year":"1998","journal-title":"Psychother Psychosom."},{"issue":"2 Suppl","key":"10.1016\/j.rpsm.2015.11.003_bib1785","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1177\/0269881107087346","article-title":"Antipsychotics and hyperprolactinaemia: Clinical recommendations","author":"Peveler","year":"2008","journal-title":"J PsychopharmacolV 22"}],"container-title":["Revista de Psiquiatr\u00eda  y Salud Mental"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1888989116000239?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1888989116000239?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T11:30:02Z","timestamp":1761823802000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1888989116000239"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7]]},"references-count":178,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,7]]}},"alternative-id":["S1888989116000239"],"URL":"https:\/\/doi.org\/10.1016\/j.rpsm.2015.11.003","relation":{},"ISSN":["1888-9891"],"issn-type":[{"value":"1888-9891","type":"print"}],"subject":[],"published":{"date-parts":[[2016,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Consenso espa\u00f1ol sobre los riesgos y detecci\u00f3n de la hiperprolactinemia iatrog\u00e9nica por antipsic\u00f3ticos","name":"articletitle","label":"Article Title"},{"value":"Revista de Psiquiatr\u00eda  y Salud Mental","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rpsm.2015.11.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 SEP y SEPB. Published by Elsevier Espa\u00f1a, S.L.U. All rights reserved.","name":"copyright","label":"Copyright"}]}}